Quadrant Capital Group
MRNA icon

Quadrant Capital Group’s Moderna MRNA Stock Holding History

Quadrant Capital Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$524K Buy
+2,422
New +$261K 0.01% 847
2026
Q2 		– Sell
-2,194
Closed -$111K – 2060
2026
Q1 		$111K Buy
2,194
+402
+22% +$18.8K ﹤0.01% 1453
2025
Q4 		$52.8K Sell
1,792
-9,455
-84% -$257K ﹤0.01% 1663
2025
Q3 		$291K Buy
+11,247
New +$314K 0.01% 1143
2025
Q2 		– Sell
-4,262
Closed -$121K – 2111
2025
Q1 		$121K Buy
4,262
+1,742
+69% +$61.8K ﹤0.01% 1482
2024
Q4 		$105K Buy
2,520
+697
+38% +$33.3K 0.01% 1028
2024
Q3 		$122K Sell
1,823
-1,508
-45% -$138K 0.01% 958
2024
Q2 		$396K Buy
3,331
+415
+14% +$52.5K 0.03% 388
2024
Q1 		$311K Buy
2,916
+244
+9% +$24.6K 0.02% 455
2023
Q4 		$266K Buy
2,672
+187
+8% +$15.7K 0.02% 485
2023
Q3 		$257K Buy
2,485
+697
+39% +$77.7K 0.03% 429
2023
Q2 		$217K Sell
1,788
-438
-20% -$58.4K 0.02% 479
2023
Q1 		$342K Sell
2,226
-465
-17% -$76.7K 0.04% 357
2022
Q4 		$483K Buy
2,691
+986
+58% +$161K 0.05% 242
2022
Q3 		$202K Sell
1,705
-192
-10% -$29.1K 0.03% 427
2022
Q2 		$271K Sell
1,897
-38
-2% -$5.43K 0.04% 346
2022
Q1 		$333K Buy
1,935
+213
+12% +$35.9K 0.04% 323
2021
Q4 		$437K Sell
1,722
-47
-3% -$13.7K 0.05% 243
2021
Q3 		$681K Buy
1,769
+299
+20% +$110K 0.1% 151
2021
Q2 		$345K Buy
1,470
+134
+10% +$23.9K 0.05% 253
2021
Q1 		$175K Buy
1,336
+288
+27% +$41.7K 0.03% 389
2020
Q4 		$109K Buy
1,048
+423
+68% +$42.8K 0.02% 470
2020
Q3 		$44K Buy
625
+55
+10% +$3.84K 0.01% 701
2020
Q2 		$37K Sell
570
-1,225
-68% -$67.1K 0.01% 836
2020
Q1 		$54K Buy
+1,795
New +$41.3K 0.01% 851

Other funds holding MRNA

Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Beau Ventures, LLc
Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
LAI
Legal Advantage Investments Los Altos Hills, California $468M AUM 7.83% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Quadrant Capital Group's MRNA Position: Q3 2026 in Review

Quadrant Capital Group opened a new position in Moderna (MRNA) in Q3 2026: 2,422 shares worth $524K. The stake represents 0.01% of the portfolio and ranks #847 among its holdings. This is a return to the name: Quadrant Capital Group previously reported a position in MRNA as recently as Q1 2026.

Quadrant Capital Group first reported a position in MRNA in Q1 2020 and has held it in 25 quarters since. The position peaked at $681K in Q3 2021. 221 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Quadrant Capital Group held 2,422 shares of Moderna worth $524K as of Q3 2026.
  • Moderna was a new Quadrant Capital Group position in Q3 2026.
  • Moderna made up 0.01% of Quadrant Capital Group's portfolio in Q3 2026, its #847 holding.
  • Quadrant Capital Group first reported a position in Moderna in Q1 2020 and has held it in 25 quarters since.
  • Quadrant Capital Group's Moderna position peaked at $681K in Q3 2021.
  • 221 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Quadrant Capital Group's 13F filing for Q3 2026, filed 20 Oct 2026.